Fig. 7

Effects of statin-Dex treatment on the levels of anti-R97–116 peptide IgG antibody and its subtype in serum. Rats treated with statin-Dex had lower levels of serum anti-R97–116 IgG, IgG2a, and IgG2b antibodies compared with control-Dex group rats (for IgG *p < 0.05 on day 21 p.i., ***p < 0.001 on day 43 p.i.; for IgG2a ***p < 0.001 on day 32 p.i., *p < 0.05 on day 43 p.i.; for IgG2b ***p < 0.001 on day 21 p.i., **p < 0.01 on day 43 p.i.) and control group rats (for IgG ^# p < 0.05 on day 43 p.i.; for IgG2a ^# p < 0.05 on days 32 and 43 p.i.; for IgG2b ^# p < 0.05 on days 21 and 43 p.i.). No significant difference in serum anti-R97–116 IgG antibody and its subtype was found between control-Dex group rats and control EAMG rats at different time points. Meanwhile, there was no statistical difference for anti-R97–116 IgG1 antibody among the three groups at different time points. Each serum was tested in triplicate. All results are expressed as mean ± SD (n = 5 rats per group)